Showing results (41-50 of 61) with videos related to
Sort By:
Pageof 7
Medicina (Kaunas, Lithuania)|September 28, 2021
Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case ReportNicole Marie Del Toro-Pagán, Adriana Matos, David Thacker, et al.Pharmacy (Basel, Switzerland)|May 24, 2020
Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the ElderlyDavid L Bankes, Hubert Jin, Stephanie Finnel, et al.Pharmaceutics|September 9, 2020
Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical PracticeMalavika Deodhar, Sweilem B Al Rihani, Meghan J Arwood, et al.Journal of Clinical Medicine|August 14, 2020
Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with PolypharmacySweilem B Al Rihani, Matt K Smith, Ravil Bikmetov, et al.Pharmacogenomics and Personalized Medicine|November 17, 2022
Utilizing Pharmacogenomics Results to Determine Opioid Appropriateness and Improve Pain Management in a Patient with OsteoarthritisKatie Pizzolato, David Thacker, Nicole Marie Del Toro-Pagán, et al.The American Journal of Case Reports|February 22, 2023
Pharmacogenetic Testing in a 70-Year-Old Woman with Polypharmacy and Multiple Comorbidities: A Case ReportJayson P Jessop, Joshua Russell, Adriana DeJesus, et al.Medicina (Kaunas, Lithuania)|October 23, 2021
Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson's DiseaseKatie Pizzolato, David Thacker, Nicole Del Toro-Pagán, et al.The American Journal of Managed Care|September 16, 2021
Association of the MedWise Risk Score with health care outcomesVeronique Michaud, Matt K Smith, Ravil Bikmetov, et al.Clinical and Translational Science|March 31, 2021
Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation studyMatt K Smith, Ravil Bikmetov, Sweilem B Al Rihani, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 3, 2024
Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulationMarian Klose, Rodrigo Cristofoletti, Carolina de Miranda Silva, et al.Pageof 7